ConMed forecasts 2026 adjusted EPS of $4.54 to $4.61 as it tightens organic growth outlook to 5% to 5.5% (NYSE:CNMD)
CONMED reported Q3 2026 net revenue of $335.6M, with adjusted EPS forecasted between $4.54 and $4.61 for 2026. The company revised its organic growth outlook to 5% to 5.5%. CEO Patrick Beyer noted mixed sales but stronger underlying growth excluding exited GI products.
How this was made
The 30-second read
Why it matters
The revised outlook suggests tighter margins and slower top‑line growth, likely prompting a re‑rating by analysts.
Market read
The guidance update is a material corporate event that can move CNMD and related medical device stocks.
What to watch
Potential cost‑saving initiatives and upcoming product launches not reflected in the guidance.
Background
ConMed's earnings call highlighted mixed sales and a focus on organic growth after exiting GI products.
Ticker impact
ConMed issued 2026 adjusted EPS guidance of $4.54‑$4.61 and trimmed organic growth outlook to 5‑5.5%, a fresh corporate forecast.
likely pressure as investors price in slower growth and lower EPS
The new EPS range and growth outlook are lower than consensus, prompting sell‑side coverage and potential short‑term downside.
Market effects
May signal slower demand in medical device sector, affecting peers.
U.S. healthcare stocks could see modest pullback.
Limited to medical device industry.
Counterpoint
If the market overreacts, the lower guidance could be a buying opportunity on a dip.
Key entities
- personPatrick Beyer
CEO of ConMed who presented the guidance.
